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The orientation of the carboxyl terminal region of the Escherichia coli proline carrier in the cytoplasmic membrane was 
studied. The B-galactosidase moiety of the PutP-LncZ fusion protein [(1987) J. Biol. Chem. 262, 1410&14104] was ex- 
posed outside the inside-out vesicles and inside the right-side-out vesicles. A site-directed antibody raised against a syn- 
thetic peptide corresponding to the putative carboxyl terminal region of the carrier reacted preferentially with the inside- 
out vesicles prepared from a wild-type proline carrier overproducing strain and less with the right-side-out vesicles. These 
results indicate that the carboxyl terminus of the proline carrier is exposed to the cytoplasmic side of the membrane. 
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1. INTRODUCTION 
The high-affinity transport of proline in E. coli 
is mediated by a major proline carrier identified as 
an integral protein in the cytoplasmic membrane 
[ll. This is a typical secondary active transport 
system which couples a downhill movement of Na+ 
(or Li+) to an uphill movement of proline across 
the membrane [2-51. Also, the carrier binds pro- 
line in an H+- and Na+ (or Li+)-dependent manner 
under non-energized conditions [6,7]. The proline 
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carrier is encoded by the p&P gene [8]. The 
nucleotide sequence of the putP gene was deter- 
mined, and the deduced amino acid sequence in- 
dicated that the carrier consists of a single 
polypeptide with an A4, of 54343 and may contain 
12 membrane spanning segments [9]. 
The proline carrier was purified by taking ad- 
vantage of a site-cleavable fusion protein of pro- 
line carrier and ,&galactosidase linked through a 
collagen linker (P&P-LacZ fusion protein) in a 
functional form [5, lo]. The &galactosidase activi- 
ty of the fusion protein was cryptic in intact cells 
and could be detected upon permeabilization, sug- 
gesting that the carboxyl terminus of the proline 
carrier is exposed to the cytoplasmic side of the 
membrane [lo]. However, a possible mislocation 
of the carboxyl terminus due to the bulky ,B- 
galactosidase moiety could still be argued. In this 
study we demonstrated the orientation of the car- 
boxy1 terminus of the wild-type proline carrier by 
an immunochemical approach. 
2. EXPERIMENTAL 
2.1. Bacterial strains and preparation of membrane vesicles 
ST3019, a putP_ strain, and ST3015, a proline carrier over- 
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producing strain, were grown as described [l]. ST3039, which 
produces the collagen-linked PutP-LacZ fusion protein, was 
grown as described [lo]. Cells were harvested at late log phase. 
RSOV [11] and ISOV [12] were prepared and stored at - 80°C 
until use. A syringe filled with a to-gauge needle was used to 
suspend the vesicles during preparation. The amount of the pro- 
line carrier in each vesicle preparation from ST3015 was 
estimated by proline binding assay as described [lo]. 
2.2. Orientation of the PutP-LacZ fusion protein 
The orientation of the ,&galactosidase moiety of the PutP- 
La& fusion protein was examined by using RSOV and ISOV 
from ST3039 essentially as described [lo]. The suspension of 
RSOV or ISOV (0.25 mg protein) in 0.5 ml 25 mM Tris-HCl 
(pH 7.5) containing 2.5 mM CaClz was treated with 5 units of 
Ckxtridium histolyticum collagenase (Sigma) to release the .&- 
galactosidase moiety exposed outside the vesicles. The reaction 
was stopped with 6 mM EGTA, and the reaction mixture was 
centrifuged at 360000 x g for 20 min. The precipitate was 
resuspended in 0.5 ml 25 mM Tris-HCl (pH 7.5) and 
permeabilized with 0.01% of dodecyl-@-D-maltoside 
(Calbiochem-Behring). Then ,&galactosidase activities of the 
supernatant and the precipitate were measured with oNPG as 
substrate. 
2.3. Pre~a~t~o~ of anti -Ct-antibodies 
A synthetic peptide corresponding to the putative Ct 
(YHSAPPSRLQES) of the proline carrier with a cysteine 
residue added to the amino terminus and the Ct-peptide con- 
jugated to KLH were kindly supplied by Fujiya Co. Ltd. 
(Tokyo). The conjugate (0.3 mg) was emulsified with Freund’s 
complete adjuvant (Wako Pure Chemicals) and injected into 
lymph nodes of male Japanese white rabbits [ 131. They received 
intradermal booster injection of the conjugate (0.8 mg) 
emulsified with Freund’s incomplete adjuvant (Wako Pure 
Chemicals) every 10 days for J-10 times and bled. Im- 
munoglobulin (IgG) fraction was precipitated from the antisera 
with ammonium sulfate and affinity-purified with immunosor- 
bent prepared by conjugation of the Ct-peptide to activated 
CH-Sepharose 4B (Pha~acia). The anti-Ct-IgG obtained was 
concentrated by ultrafiltration (Centricon 30, Amicon) and 
dialyzed against 0.15 M PBS [14]. 
ST3019 in PBS containing 0.1% BSA were preincubated with 
0.3 @g/ml of the biotinylated IgG for 1 h at 37’C. Each well of 
a microtiter plate (Immulon 2, Dinatec laboratories) was coated 
with 50 pi of the Ct peptide (1 pg/ml in 50 mM sodium car- 
bonate, pH 9.6) for overnight at 4°C and blocked by incubation 
with 10% skimmed milk-PBS for 1 h at 37°C. After washing 
with PBS, each well was incubated with 50 ~1 of the mixture of 
the IgG and the vesicles for 1 h at 37°C. The IgG bound to each 
well was assayed as described [16] with avidine-peroxidase con- 
jugate (Vector). Absorbance at 492 nm was determined in 
Chromo Scan ELISA reader (MTP32, Corona). There was a 
linearity between the amount of the IgG used below 0.3 pg/ml 
and the resultant coloration. 
2.6. Protein measurement 
IgG was determined by measurement of absorbance at 
280 nm. Other proteins were measured as described [17] with 
BSA as a standard. 
3. RESULTS AND DISCUSSION 
3.1. Orientation of the PutP-LacZ fusion protein 
The orientation of the PutP-LacZ fusion protein 
was determined taking advantage of the cleavabili- 
ty of the collagen linker. As in table 1, 84% of the 
@-galactosidase activity of the fusion protein in 
ISOV was released by collagenase from ISOV but 
only 14% of that was released from RSOV, in- 
dicating that the ,&galactosidase moiety resides in 
the cytoplasmic side of the membrane. This fin- 
ding was consistent with the previous observation 
that the ,&galactosidase activity was cryptic in the 
cell [lo]. It also suggested that the fusion protein 
seldom undergoes dislocation during vesicle for- 
mation. 
3.2. specificity of the ant~~o~i~ 
The antisera and the purified anti-Ct-IgG cross 
reacted with the Ct-peptide and the Ct-peptide- 
2.4. Assay of antibodies 
The antisera and purified IgG were tested by dot-blot and Table 1 
Western blot analyses. The Ct-peptide and Ct-KLH conjugate 
were spotted on nitrocellulo~ membrane filters for dot-blot 
analysis. The membrane proteins in RSOV or ISOV from 
ST3015 or ST3019 were blotted onto a nitrocellulose membrane 
filter [15] in the presence of 0.05% SDS for Western blot 
analysis. Then ELISA was performed with alkaline 
phosphatase-conjugated anti-rabbit (Fc) IgG according to the 
instruction of the manufacturer (ProtoBlot immunoscreening 
system, Promega). 





(nmol oNPG hydrolyzed/ 
fraction-’ per min-‘) 
Ratio 
sup : PPt) 
Sunernatant Precipitate 
2.5. Determination of orientation of Ct by competitive ELBA 
The purified anti-Ct-IgG was biotinylated as described [16]. 
Disrupted vesicles were prepared by two cycles of freeze-thaw 
of vesicles (1 mg/ml of protein) in 50 mM KOH containing 
5 mM EDTA; then the pH was neutralized with HCI. Serial 
dilutions of intact and disrupted vesicles from ST3015 or 
RSOV 370 2280 14:86 
ISOV 1430 280 84: 16 
The vesicles from ST3039 were treated with collagenase and 
centrifuged. The ,&galactosidase activities of the supernatant 
and the precipitate (permeabilized) were measured. See section 
2 for details 
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Fig. 1. The specificity of the affinity-purified anti-Ct-IgG. 
Assays were made by Western blotting: lane 1, ST3019 RSOV; 
lane 2, ST3019 ISOV; lane 3, ST3015 RSOV; lane 4, ST3015 
ISOV. Each lane contained 10,~g protein. Wild-type proline 
carrier shows an apparent M, of 32000 on 10% acrylamide gel 
KLH conjugate on dot-blot analysis (data not 
shown). The affinity purified anti-Ct-IgG was 
highly specific to the proline carrier in the mem- 
brane from ST3015 and did not react with proteins 
from ST3019 (fig.1). 
The fact that the antibody raised against he syn- 
thetic peptide reacted with the proline carrier both 
in denatured state and, as mentioned later, in 
membrane-bound state suggests that the carboxyl 
30- 
CProlinel-’ (t&l)-’ 
Fig.2. Double reciprocal plots of proline binding to membrane 
vesicles. Proline binding activity of vesicles prepared from 
ST3015 was assayed by a centrifugation method. BS,, for 
proline of each preparation was estimated: 0.40 for RSOV and 
Fig.3. Ability of membrane vesicles to inhibit the antibody 
binding to the Ct-peptide. Competitive ELISA was carried out 
as in section 2. 100% of the y-axis is defined as the absorbance 
at 492 nm when no membrane vesicles were added. Membrane 
vesicles used were: ST3015 intact (0); ST3015 disrupted (0); 
ST3019 intact (A); and ST3019 disrupted (A). The same 
amount of protein of vesicles from ST3019 as those from 
0.17 nmol/mg of protein for ISOV. ST3015 were used for control experiments. 
terminal region of the carrier takes a relaxed con- 
formation similar to that of the synthetic peptide. 
It is consistent with the previous observation that 
the bulky Bgalactosidase moiety attached to the 
proline carrier had no effect on transport or bin- 
ding activity of the carrier [lo]. 
3.3. Proline binding assay of the vesicles 
The amounts of proline carrier in RSOV and 
ISOV from ST3015 were estimated from the 
numbers of BSmax for proline (legend to fig.2). The 
difference in the amounts of proline carrier bet- 
ween the two vesicle preparations was also seen on 
Western blot (fig.1, lanes 3 and 4). This must be 
due to a relative content of outer membrane, since 
RSOV were partially purified by isopycnic sucrose 
A.RSOV (A) 
--__ 
I I I I 0.0 1 0.1 1 10 
Amount of Proline Carrier (pmol BSmaxlmO 
137 
Volume 256, number 1,2 FEBS LETTERS October 1989 
centrifugation but ISOV were not. The apparent 
Kd of each preparation calculated from fig.2 was 
the same (3.7 PM). Under our assay condition the 
proline concentration was equilibrated inside and 
outside the vesicles by a carrier-mediated 
facilitated diffusion; thus we may not see a dif- 
ference in the affinity for proline between these 
two preparations. 
3.4. Orientation of wild-type proline carrier 
Degree of the exposure of the carboxyl terminus 
of proline carrier in different vesicle preparations 
was estimated by competitive ELISA in which the 
ability of vesicle preparations to inhibit the an- 
tibody binding to the Ct-peptide coated on the 
plates was measured. Fig.3B shows that the ISOV 
from ST3015 bound the antibody equally well in 
either intact or disrupted state. The RSOV from 
ST3015 bound far less IgG than the ISOV, but 
upon disruption they bound more IgG (fig.3A). 
The antibody binding to the vesicles was specific to 
the proline carrier, because the vesicles from 
ST3019 did not show antibody binding at all 
(fig.3A,B). These results indicated that the carbox- 
yl terminal region of the proline carrier resides out- 
side the ISOV and inside the RSOV; we therefore 
concluded that it is located in the cytoplasmic side 
of the membrane. 
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